Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models

  • Costa-Machado, Luis Filipe
  • García-Domínguez, Esther
  • McIntyre, Rebecca L.
  • López-Aceituno, José Luis
  • Ballesteros-González, Álvaro
  • Tapia-González, Andrea
  • Fabregat-Safont, David
  • Eisenberg, Tobias
  • Gómez, Jesús
  • Plaza, Adrian
  • Sierra-Ramírez, Aranzazu
  • Pérez, Manuel
  • Villanueva-Bermejo, David
  • Fornari, Tiziana
  • Loza, María Isabel
  • Herradón, Gonzalo
  • Hofer, Sebastian J.
  • Magnes, Christoph
  • Madeo, Frank
  • Duerr, Janet S.
  • Pozo, Oscar J.
  • Galindo, Maximo-Ibo
  • Pino, Isabel del
  • Houtkooper, Riekelt H.
  • Megías, Diego
  • Viña, José
  • Gómez-Cabrera, Mari Carmen
  • Fernández-Marcos, Pablo José
Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis., L.F.C.-M. was supported by the IMDEA Food institute and by a PhD Fellowship from the Portuguese Foundation for Science and Technology (FCT‐MCTES, SFRH/BD/124022/2016). Work in the laboratory of P.J.F.-M. was funded by the IMDEA Food Institute, the Ramón Areces Foundation (CIVP18A3891), the AECC (SIRTBIO, LABAE18008FERN), the MICINN (SAF2017-85766-R and PRPPID2020-114077RB-I00) co-funded by the European Regional Development Fund, and a Ramon y Cajal Fellowship (MICINN, RYC-2017-22335). J.L.L.-A. was funded by the Spanish Ministry of Science and Innovation (MICINN) (PTA2017‐14689‐I). Work in FreshAge laboratory was funded by: Instituto de Salud Carlos III CB16/10/00435 (CIBERFES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science; FGCSIC/PSLINTERREG/FEDER; PROMETEO/2019/097 de “Consellería de Sanitat de la Generalitat Valenciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana). Support from Ramón Areces Fundation and Soria Melguizo Foundation is also acknowledged. E.G.-D. was a recipient of a predoctoral grant financed by the Spanish Ministry (FPU18/05350). Work in the laboratory of IdP was funded by the MICINN (RTI2018-100872-J-I00) and PlaGenT excellence research program of the Valencian regional government (CIDENGENT/2019/044). Work in the laboratory of M.-I.G. was funded by PROMETEU/2018/135 from “Consellería, de Sanitat de la Generalitat Valenciana” and part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). F.M. is grateful to the Austrian Science Fund FWF (SFB-LIPOTOX F3007 & F3012, W1226, P29203, P29262, P27893, and P31727); the Austrian Federal Ministry of Education, Science and Research and the University of Graz for grants Unkonventionelle Forschung-InterFast and ysleep (BMWFW-80.109/0001-WF/V/3b/2015) and the field of excellence program BioHealth. We acknowledge support from NAWI Graz, the BioTechMed-Graz agship project EPIAge. T.E. acknowledges support from Austrian Science Fund FWF (P 33957 and TAI 602 1000). Work in the laboratory of R.H.H. was financially supported by a VIDI grant from ZonMw (no. 91715305). J.S.D. was supported by Ohio University. D.F.-S. acknowledges Ministerio de Universidades in Spain for his Margarita Salas postdoctoral grant (Ref. MGS/2021/15). The CGC group is funded by NIH Office of Research Infrastructure Programs (P40 OD010440)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pharmacological and genetic increases in liver NADPH levels ameliorate NASH progression in female mice

  • Rodríguez-Ramiro, Ildefonso
  • Pastor-Fernández, Andrés
  • López-Aceituno, José Luis
  • Garcia-Dominguez, Esther
  • Sierra-Ramirez, Aránzazu
  • Valverde, Ángela M.
  • Martínez-Pastor, Bárbara
  • Efeyan, Alejo
  • Gómez-Cabrera, M. C.
  • Viña, Jose
  • Fernandez-Marcos, Pablo J.
Non-alcoholic steatohepatitis (NASH) is one of the fastest growing liver diseases worldwide, and oxidative stress is one of NASH main key drivers. Nicotinamide adenine dinucleotide phosphate (NADPH) is the ultimate donor of reductive power to a number of antioxidant defences. Here, we explored the potential of increasing NADPH levels to prevent NASH progression. We used nicotinamide riboside (NR) supplementation or a G6PD-tg mouse line harbouring an additional copy of the human G6PD gene. In a NASH mouse model induced by feeding mice a methionine-choline deficient (MCD) diet for three weeks, both tools increased the hepatic levels of NADPH and ameliorated the NASH phenotype induced by the MCD intervention, but only in female mice. Boosting NADPH levels in females increased the liver expression of the antioxidant genes Gsta3, Sod1 and Txnrd1 in NR-treated mice, or of Gsr for G6PD-tg mice. Both strategies significantly reduced hepatic lipid peroxidation. NR-treated female mice showed a reduction of steatosis accompanied by a drop of the hepatic triglyceride levels, that was not observed in G6PD-tg mice. NR-treated mice tended to reduce their lobular inflammation, showed a reduction of the NK cell population and diminished transcription of the damage marker Lcn2. G6PD-tg female mice exhibited a reduction of their lobular inflammation and hepatocyte ballooning induced by the MCD diet, that was related to a reduction of the monocyte-derived macrophage population and the Tnfa, Ccl2 and Lcn2 gene expression. As conclusion, boosting hepatic NADPH levels attenuated the oxidative lipid damage and the exhausted antioxidant gene expression specifically in female mice in two different models of NASH, preventing the progression of the inflammatory process and hepatic injury., This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No - 832741. (Acronym Food-PPP-NAFLD). I.R-R was recipient and funded by the Marie Skłodowska-Curie grant. AP-F was a recipient of a predoctoral fellowship from the Spanish association against cancer - AECC (PRDMA18011PAST). JLL-A was funded by the Spanish Ministry of Science and Innovation (MICINN) (PTA2017‐14689‐I). PJF-M was funded by a Ramon y Cajal Award from the Spanish Ministry of Science, Innovation and Universities (MICINN) (RYC-2017-22335 financed by the MCIN/AEI/10.13039/501100011033 and by the ESF Investing in your future). Work at the laboratory of PJF-M was funded by the AECC (SIRTBIO- LABAE18008FERN) and the RETOS Program projects from the MICINN (SAF2017-85766-R and PID2020-114077RB-I00/AEI/10.13039/501100011033). E.G.-D. was a recipient of a predoctoral grant financed by the Spanish Ministry (FPU18/05350). A. M. V. is funded by Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem)., Peer reviewed